Nutriband Inc. to Present AVERSA Technology at MicroCap Rodeo Conference

Nutriband Inc. (NASDAQ: NTRB) has confirmed its participation in the MicroCap Rodeo Conference scheduled for September 25, 2025, in New York City. Company Chairman Serguei Melnik will deliver a presentation at 10 a.m. that will focus on operational highlights, growth initiatives, and the strategic direction for the company's proprietary AVERSA platform technology. The presentation will be available via live webcast, with registration open for interested parties who wish to follow the company's updates remotely.

The AVERSA technology represents a significant advancement in transdermal pharmaceutical delivery systems, specifically designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This technology can be incorporated into any transdermal patch, with Nutriband's lead product being an abuse-deterrent fentanyl patch currently under development. The company's commitment to addressing the opioid crisis through technological innovation positions it at the forefront of pharmaceutical safety solutions.

For investors and industry observers seeking additional information about Nutriband, the company maintains an online newsroom at https://ibn.fm/NTRB where the latest updates and news relating to NTRB are available. The MicroCap Rodeo Conference presentation provides an important opportunity for the company to demonstrate its progress and future plans to the investment community.

The announcement was distributed through InvestorWire, a specialized communications platform that provides advanced wire-grade press release syndication services. InvestorWire is part of the Dynamic Brand Portfolio at IBN, offering comprehensive corporate communications solutions including article syndication to more than 5,000 outlets and social media distribution to millions of followers. Additional details about InvestorWire's services can be found at https://www.InvestorWire.com.

Nutriband's participation in this conference comes at a critical time for the pharmaceutical industry, as regulatory agencies and healthcare providers increasingly prioritize abuse-deterrent formulations. The company's focus on developing safer drug delivery systems addresses a pressing public health concern while creating potential value for shareholders. The presentation will likely cover milestones achieved in the development pipeline and provide insights into the commercial potential of the AVERSA technology platform.